Let's face it. The average 35-year-old's investment portfolio should look considerably different than the average 65-year-old's. The former has plenty of time to ride out the market's inevitable ups and downs, and probably doesn't need investment income just yet. The latter, on the other hand, is likely in or nearing retirement and therefore looking for income to help pay monthly expenses.
With that as the backdrop, here's a closer look at three names that wouldn't necessarily be out of place as part of a younger person's stock holdings, but make a great deal of sense for the typical retiree.
Investors who know anything about AbbVie (NYSE: ABBV) probably know it's the name behind arthritis and Crohn's disease treatment Humira, which accounts for nearly 40% of the company's revenue. And that's a problem. Humira is AbbVie's breadwinner, but the drug is also going to start losing its most important patent protections beginning in 2023. It will lose more of that protection in the following years. This brewing revenue headwind is a big reason AbbVie shares have underperformed since 2018.
Source Fool.com